EXPERIMENTAL EVALUATION OF TIGECYCLINE AND TEIKOPLANIN IN THE TREATMENT OF IMPLANT RELATED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) OSTEOMYELITISAbstract
Treatment of implant-related MRSA osteomyelitis is a real challenge both for the physician and the patient. We evaluated the comparative efficacy of tigecycline, a novel broad-spectrum glycycline antibiotic and the glycopeptide antibiotic teicoplanin in the treatment of implant-related MRSA osteomyelitis in an experimental rat model. Implant related MRSA osteomyelitis was studied in the tibial metaphysis of 60 rats. When compared to the control groups, the number of microorganisms was found to be significantly lower in the study groups, but there was no statistically significant difference between tigecycline and teicoplanin. respectively. Tigecycline with its good tissue penetration and lower side effects were found to be as effective as teicoplanin in implant-related MRSA osteomyelitis, even if the implant is retained. It could be considered as an alternative to glycopeptides because of the efficacy and because of the lower adverse effects in long term usage. Further studies are warranted to suggest a standard medical treatment for implant-related osteomyelitis.
Z. Orhan *, E. Değirmenci, B. Oktas, O. Karaduman, G. Kır and L. Mülazımoğlu
Department of Orthopaedics and Traumatology, Duzce University, Duzce Medical School, Duzce, Turkey.
04 April 2014
24 May 2014
17 July 2014
01 October 2014